DK1578771T3 - Remodellering og glycokonjugering af peptider - Google Patents
Remodellering og glycokonjugering af peptiderInfo
- Publication number
- DK1578771T3 DK1578771T3 DK02795509.5T DK02795509T DK1578771T3 DK 1578771 T3 DK1578771 T3 DK 1578771T3 DK 02795509 T DK02795509 T DK 02795509T DK 1578771 T3 DK1578771 T3 DK 1578771T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycoconjugation
- remodeling
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000007634 remodeling Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2445—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32852301P | 2001-10-10 | 2001-10-10 | |
US34469201P | 2001-10-19 | 2001-10-19 | |
US33430101P | 2001-11-28 | 2001-11-28 | |
US33423301P | 2001-11-28 | 2001-11-28 | |
US38729202P | 2002-06-07 | 2002-06-07 | |
US39177702P | 2002-06-25 | 2002-06-25 | |
US39659402P | 2002-07-17 | 2002-07-17 | |
US40424902P | 2002-08-16 | 2002-08-16 | |
US40752702P | 2002-08-28 | 2002-08-28 | |
PCT/US2002/032263 WO2003031464A2 (en) | 2001-10-10 | 2002-10-09 | Remodeling and glycoconjugation of peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1578771T3 true DK1578771T3 (da) | 2013-06-10 |
Family
ID=27578810
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02795509.5T DK1578771T3 (da) | 2001-10-10 | 2002-10-09 | Remodellering og glycokonjugering af peptider |
DK10184886.9T DK2322229T3 (da) | 2001-10-10 | 2002-10-09 | Remodellering og glycokonjugering af Faktor IX |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10184886.9T DK2322229T3 (da) | 2001-10-10 | 2002-10-09 | Remodellering og glycokonjugering af Faktor IX |
Country Status (20)
Country | Link |
---|---|
US (3) | US7416858B2 (da) |
EP (7) | EP2279753B1 (da) |
JP (8) | JP5232352B2 (da) |
CN (3) | CN1635901B (da) |
AU (2) | AU2002360264B2 (da) |
BE (1) | BE2014C004I2 (da) |
BR (1) | BRPI0213207B1 (da) |
CA (1) | CA2462930C (da) |
DK (2) | DK1578771T3 (da) |
ES (9) | ES2538342T3 (da) |
FR (1) | FR14C0007I2 (da) |
HK (4) | HK1079797A1 (da) |
IL (3) | IL161251A0 (da) |
LU (1) | LU92359I2 (da) |
MX (1) | MXPA04003333A (da) |
NL (1) | NL300912I2 (da) |
NZ (1) | NZ532027A (da) |
PT (2) | PT2279753E (da) |
SG (2) | SG177002A1 (da) |
WO (1) | WO2003031464A2 (da) |
Families Citing this family (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
ES2484966T3 (es) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7112410B1 (en) | 2001-08-29 | 2006-09-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor TR21 and methods based thereon |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
JP5232352B2 (ja) | 2001-10-10 | 2013-07-10 | ノボ ノルデイスク エイ エス | ペプチドの改造および複合糖質化 |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
ES2381104T3 (es) * | 2001-10-29 | 2012-05-23 | Crucell Holland B.V. | Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003057179A2 (en) | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
EP1527080B1 (en) * | 2002-08-01 | 2012-06-20 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
AU2003255544A1 (en) | 2002-08-20 | 2004-03-11 | Biotie Therapies Corp. | Tumor specific oligosaccharide epitopes and use thereof |
ES2343518T3 (es) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
KR20050073559A (ko) | 2002-10-16 | 2005-07-14 | 더 스크립스 리서치 인스티튜트 | 당단백질 합성 |
WO2004043381A2 (en) * | 2002-11-08 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods for prolonging survival of platelets |
US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
US7803777B2 (en) * | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
WO2004091487A2 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Hemophilia treatment by inhalation of coagulation factors |
JP4674702B2 (ja) * | 2003-04-09 | 2011-04-20 | バイオジェネリクス エージー | グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド |
MXPA05011832A (es) | 2003-05-09 | 2006-02-17 | Neose Technologies Inc | Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano. |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
EP2441465B1 (en) | 2003-10-24 | 2014-01-15 | Nora Therapeutics, Inc. | Compositions and methods for healthy pregnancy |
US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
US7507573B2 (en) * | 2003-11-14 | 2009-03-24 | Vib, Vzw | Modification of protein glycosylation in methylotrophic yeast |
US20070258986A1 (en) * | 2003-11-19 | 2007-11-08 | Govt of the US as represented by the secretary, | Targeted Delivery System for Bioactive Agents |
WO2005072371A2 (en) * | 2004-01-26 | 2005-08-11 | Neose Technologies, Inc. | Branched polymeric sugars and nucleotides thereof |
US20080305992A1 (en) * | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20070254834A1 (en) * | 2003-11-24 | 2007-11-01 | Defrees Shawn | Glycopegylated Erythropoietin |
BRPI0416950B8 (pt) | 2003-12-01 | 2021-05-25 | Novo Nordisk Healthcare Ag | métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida. |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
JP4738346B2 (ja) * | 2003-12-03 | 2011-08-03 | ノヴォ ノルディスク アー/エス | GlycoPEG化された第IX因子 |
WO2005055946A2 (en) * | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
PL2298287T3 (pl) | 2003-12-19 | 2019-02-28 | Novo Nordisk Health Care Ag | Stabilizowane kompozycje polipeptydów czynnika VII |
CA2552892C (en) * | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
JP4871739B2 (ja) * | 2004-01-26 | 2012-02-08 | ノヴォ ノルディスク アー/エス | 分枝高分子糖およびそのヌクレオチド |
US8778880B2 (en) * | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
PL1729795T3 (pl) * | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
EP1744786A2 (en) * | 2004-03-23 | 2007-01-24 | Amgen Inc. | Chemically modified protein compositions and methods |
KR20070008645A (ko) | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 o-연결된 단백당형 및 그들의 제조 방법 |
US20050287639A1 (en) | 2004-05-17 | 2005-12-29 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
AU2005260763B2 (en) * | 2004-06-30 | 2011-12-22 | Nektar Therapeutics | Polymer-factor IX moiety conjugates |
AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
EP1771066A2 (en) * | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
WO2006020372A2 (en) * | 2004-07-23 | 2006-02-23 | Neose Technologies, Inc. | Enzymatic modification of glycopeptides |
ATE534290T1 (de) * | 2004-09-07 | 2011-12-15 | Velico Medical Inc | Apparat zur verlängerung der überlebensdauer von blutplättchen |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
US20060073152A1 (en) * | 2004-10-05 | 2006-04-06 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
CA2626363A1 (en) * | 2004-10-15 | 2006-04-27 | Zymequest, Inc. | Compositions and methods for prolonging survival of platelets |
AU2006304496B2 (en) * | 2004-10-15 | 2013-07-11 | Velico Medical, Inc. | Compositions and methods for prolonging survival of platelets |
JP2008516637A (ja) | 2004-10-20 | 2008-05-22 | ザ スクリップス リサーチ インスティテュート | 真正細菌へのn−アセチルガラクトサミンアミノ酸のインビボ部位特異的組込み |
HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
US20090054623A1 (en) * | 2004-12-17 | 2009-02-26 | Neose Technologies, Inc. | Lipo-Conjugation of Peptides |
EP1831242B1 (en) | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
WO2006074279A1 (en) * | 2005-01-06 | 2006-07-13 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
JP4951527B2 (ja) * | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
AU2005325768A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
WO2006086823A1 (en) * | 2005-02-15 | 2006-08-24 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
EP1861124A2 (en) * | 2005-03-11 | 2007-12-05 | Fresenius Kabi Deutschland GmbH | Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch |
AU2006226782B2 (en) * | 2005-03-24 | 2011-12-08 | Ratiopharm Gmbh | Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms |
US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
US8772044B2 (en) * | 2005-03-31 | 2014-07-08 | The Noguchi Institute | Method of negative-ion MALDI analysis of neutral labeled sugars and screening disease markers |
US20070154992A1 (en) * | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
AU2006239315B2 (en) | 2005-04-28 | 2012-03-01 | Ventana Medical Systems, Inc. | Enzymes conjugated to antiobodies via a PEG heterobifuctional linker |
US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
MX2008002395A (es) * | 2005-08-19 | 2008-03-18 | Neose Technologies Inc | Factor vii y factor viia glicopegilados. |
US20070041979A1 (en) * | 2005-08-19 | 2007-02-22 | Raju T S | Proteolysis resistant antibody preparations |
JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第vii因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
EP1926817A2 (en) | 2005-09-14 | 2008-06-04 | Novo Nordisk Health Care AG | Human coagulation factor vii polypeptides |
AU2006304856A1 (en) * | 2005-10-21 | 2007-04-26 | Synageva Biopharma Corp. | Glycolated and glycosylated poultry derived therapeutic proteins |
WO2007056191A2 (en) * | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
US8247530B2 (en) * | 2005-11-08 | 2012-08-21 | Palatin Technologies, Inc. | N-alkylated cyclic peptide melanocortin agonists |
CN104090095B (zh) | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
JP2009528988A (ja) † | 2006-02-10 | 2009-08-13 | ライフ テクノロジーズ コーポレーション | 翻訳後修飾されたタンパク質の標識及び検出方法 |
WO2007133855A2 (en) * | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
EP2010222A1 (en) * | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
US8198045B2 (en) | 2006-04-19 | 2012-06-12 | Biogenerix Ag | Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms |
JP5313129B2 (ja) | 2006-05-02 | 2013-10-09 | アロザイン, インコーポレイテッド | 非天然アミノ酸置換ポリペプチド |
AU2007258609B2 (en) | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20100173323A1 (en) * | 2006-06-09 | 2010-07-08 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
AR078117A1 (es) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
CN101516388B (zh) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
EP3299033A1 (en) | 2006-07-25 | 2018-03-28 | Lipoxen Technologies Limited | N-terminal polysialylation |
JP2010505874A (ja) * | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
MX2009003470A (es) | 2006-10-04 | 2009-04-14 | Novo Nordisk As | Azucares y glicopeptidos pegilados enlazados a glicerol. |
US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
IL243117B2 (en) | 2007-01-18 | 2023-03-01 | Genzyme Corp | Oligosaccharides containing an amino group and their conjugates |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
AU2008232937B2 (en) * | 2007-03-30 | 2012-09-27 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
US9395352B2 (en) | 2007-04-06 | 2016-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Devices and methods for target molecule characterization |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
MX2009013259A (es) * | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
WO2009012502A1 (en) * | 2007-07-19 | 2009-01-22 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Self- anchoring mems intrafascicular neural electrode |
EP2185701A4 (en) * | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
UA98001C2 (uk) | 2007-08-27 | 2012-04-10 | Биодженерикс Аг | Рідка лікарська форма кон'югата полімер-g-csf |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
GB2467700A (en) * | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
EP2230900A4 (en) * | 2008-01-07 | 2013-01-09 | Synageva Biopharma Corp | GLYCOSYLATION IN BIRDS |
US20100286067A1 (en) * | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
WO2009117517A2 (en) | 2008-03-18 | 2009-09-24 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Nanopore and carbon nanotube based dna sequencer |
US8628649B2 (en) | 2008-03-18 | 2014-01-14 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Nanopore and carbon nanotube based DNA sequencer and a serial recognition sequencer |
WO2009158511A1 (en) * | 2008-06-25 | 2009-12-30 | Bayer Healthcare Llc | Factor viii muteins with reduced immunogenicity |
ES2442024T3 (es) | 2008-07-15 | 2014-02-07 | Academia Sinica | Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados |
US8968540B2 (en) | 2008-10-06 | 2015-03-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Trans-base tunnel reader for sequencing |
CN105879047A (zh) | 2008-12-16 | 2016-08-24 | 建新公司 | 寡糖-蛋白缀合物 |
MX2011007929A (es) * | 2009-01-28 | 2011-08-17 | Smartcells Inc | Sistemas basados en conjugados para entrega farmacologica controlada. |
SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
US20120035120A1 (en) | 2009-03-25 | 2012-02-09 | Seneb Biosciences, Inc. | Glycolipids as treatment for disease |
WO2010115866A1 (en) | 2009-04-06 | 2010-10-14 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
EP2442831B9 (en) | 2009-06-16 | 2016-05-11 | Glythera Limited | Materials and methods relating to glycosylation of a therapeutic polypeptide |
EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
KR102068133B1 (ko) | 2009-07-27 | 2020-01-20 | 박스알타 인코퍼레이티드 | 혈액 응고 단백질 복합체 |
WO2011018515A1 (en) | 2009-08-14 | 2011-02-17 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
US8697844B2 (en) | 2009-11-24 | 2014-04-15 | Novo Nordisk A/S | Method of purifying pegylated proteins |
US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
RU2012127383A (ru) * | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
JP2013519699A (ja) | 2010-02-16 | 2013-05-30 | ノヴォ ノルディスク アー/エス | 因子viii融合タンパク質 |
WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
MX2012010148A (es) | 2010-03-04 | 2013-01-22 | Pfenex Inc | Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. |
AU2011235210B2 (en) | 2010-04-01 | 2015-07-16 | Pfenex Inc. | Methods for G-CSF production in a Pseudomonas host cell |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US8962345B2 (en) * | 2010-05-21 | 2015-02-24 | The United States Of America As Represented By The Secretary Of Commerce | Method of characterizing glycans attached to glycoproteins |
TW201212938A (en) | 2010-06-30 | 2012-04-01 | Novo Nordisk As | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
CN102971006A (zh) | 2010-07-15 | 2013-03-13 | 诺沃—诺迪斯克有限公司 | 稳定的因子viii变体 |
WO2012015692A2 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
WO2012013823A2 (en) | 2010-07-30 | 2012-02-02 | Glycode | A yeast artificial chromosome carrying the mammalian glycosylation pathway |
ES2534936T3 (es) | 2010-08-02 | 2015-04-30 | Ratiopharm Gmbh | Método para producir y purificar una sialiltransferasa soluble activa |
CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
EP3466968A1 (en) * | 2010-09-15 | 2019-04-10 | Stichting Sanquin Bloedvoorziening | Factor viii variants having a decreased cellular uptake |
CN103221429A (zh) | 2010-09-22 | 2013-07-24 | 诺沃—诺迪斯克有限公司 | 治疗因子viii抗体 |
US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
EP2651433A1 (en) | 2010-12-16 | 2013-10-23 | Novo Nordisk A/S | Aqueous factor viii solution |
PT2654794T (pt) | 2010-12-22 | 2020-06-11 | Baxalta Inc | Materiais e métodos para conjugação de um derivado de ácido gordo solúvel em água a uma proteína |
CN103221537A (zh) * | 2011-01-06 | 2013-07-24 | 约翰·霍普金斯大学 | 在哺乳动物细胞中产生具有延长的循环半衰期的重组糖蛋白的方法 |
EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
AU2012220890A1 (en) * | 2011-02-25 | 2013-08-29 | Merck Sharp & Dohme Corp. | Yeast strain for the production of proteins with modified O-glycosylation |
EP2681237A1 (en) | 2011-03-01 | 2014-01-08 | Novo Nordisk A/S | Antagonistic dr3 ligands |
RU2013142015A (ru) | 2011-03-02 | 2015-04-10 | Ново Нордиск А/С | Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов |
DK2681245T3 (da) | 2011-03-03 | 2018-08-13 | Zymeworks Inc | Multivalent heteromultimert scaffold-design og konstruktioner |
WO2012127045A1 (en) | 2011-03-23 | 2012-09-27 | Glycode | A yeast recombinant cell capable of producing gdp-fucose |
TR201905909T4 (tr) | 2011-04-19 | 2019-05-21 | Pfizer | Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları. |
WO2012158965A2 (en) * | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
WO2012158962A2 (en) | 2011-05-18 | 2012-11-22 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
WO2012164034A1 (en) | 2011-05-31 | 2012-12-06 | Probiogen Ag | Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders |
WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
SI2717898T1 (sl) | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
HUE029855T2 (en) | 2011-07-05 | 2017-04-28 | Bioasis Technologies Inc | p97 antibody conjugates |
EP3321281B1 (en) | 2011-08-05 | 2019-11-27 | biOasis Technologies Inc | P97 fragments with transfer activity |
IN2014CN02448A (da) | 2011-09-23 | 2015-06-19 | Novo Nordisk As | |
JP6153470B2 (ja) * | 2011-10-01 | 2017-06-28 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
KR101456174B1 (ko) * | 2011-10-18 | 2014-11-03 | 한국생명공학연구원 | 용해도가 증가된 비―퀴논 젤다나마이신 당전이 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이의 열충격 단백질(Hsp90) 에이티피아제(ATPase) 활성 저해용 약학적 조성물 |
WO2013058582A2 (ko) * | 2011-10-18 | 2013-04-25 | 한국생명공학연구원 | 당전이 효소를 이용한 안사마이신 배당체의 제조방법 |
US9034829B1 (en) | 2011-10-27 | 2015-05-19 | Northwestern University | pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics |
CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
DK2822577T3 (da) | 2012-02-15 | 2019-04-01 | Bioverativ Therapeutics Inc | Rekombinante faktor viii-proteiner |
EP3564260B1 (en) | 2012-02-15 | 2022-10-19 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
CA2865170C (en) | 2012-02-21 | 2020-12-22 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
EP2841091A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
CN102786030B (zh) * | 2012-07-06 | 2014-03-12 | 江苏大学 | 一种通过溶剂处理制备多肽纳米薄膜的方法 |
AU2013289881B2 (en) | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
AU2013296557B2 (en) | 2012-07-31 | 2019-04-18 | Bioasis Technologies Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US9732367B2 (en) | 2012-09-24 | 2017-08-15 | Medimmune Limited | Cell lines |
WO2014059144A1 (en) | 2012-10-10 | 2014-04-17 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Systems and devices for molecule sensing and method of manufacturing thereof |
US20150273027A1 (en) | 2012-10-10 | 2015-10-01 | Novo Nordisk Healthcare Ag | Liquid pharmaceutical composition of factor vii polypeptide |
EP2906693A1 (en) | 2012-10-15 | 2015-08-19 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag(股份有限公司) | 因子vii缀合物 |
EP2922877B1 (en) | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
CN117903257A (zh) | 2012-11-20 | 2024-04-19 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
WO2014088836A1 (en) | 2012-12-03 | 2014-06-12 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
CN103044509B (zh) * | 2013-01-05 | 2015-04-01 | 宁辉 | γ-胞嘧啶核苷-5’-三磷酸二钠结晶化合物、其制备方法及其药物组合物 |
CN105189555B (zh) * | 2013-03-11 | 2020-07-24 | 建新公司 | 高度糖基化的结合多肽 |
ES2774549T3 (es) | 2013-03-13 | 2020-07-21 | Bioasis Technologies Inc | Fragmentos de P97 y usos de los mismos |
CN105209497B (zh) | 2013-03-15 | 2021-09-07 | 诺和诺德股份有限公司 | 能够特异性结合组织因子途径抑制物上的两个表位的抗体 |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
DK2991683T3 (da) * | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | Konjugater af et glykoprotein eller en glykan med en toksisk ladning |
EP2994164B1 (en) * | 2013-05-08 | 2020-08-05 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
EP3013365B1 (en) | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
US9352021B2 (en) | 2013-08-28 | 2016-05-31 | Cytonics Corporation | Systems, compositions, and methods for transplantation and treating conditions |
JP6486368B2 (ja) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化 |
BR112016007176A2 (pt) | 2013-10-04 | 2018-01-23 | Merck Sharp & Dohme | conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete |
WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
US20160235861A1 (en) * | 2013-10-14 | 2016-08-18 | SynAffix. B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
BR112016008039A2 (pt) | 2013-10-15 | 2017-10-17 | Novo Nordisk Healthcare Ag | polipeptídeos do fator vii da coagulação |
US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
AU2015206370A1 (en) | 2014-01-16 | 2016-07-07 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US20170009266A1 (en) * | 2014-01-24 | 2017-01-12 | Synaffix B.V. | Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby |
US11168085B2 (en) | 2014-01-24 | 2021-11-09 | Synaffix B.V. | Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne |
WO2015112016A1 (en) | 2014-01-24 | 2015-07-30 | Synaffix B.V. | Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne |
BR112016017933A2 (pt) | 2014-02-03 | 2017-10-10 | Bioasis Technologies Inc | ?proteínas de fusão p97? |
AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
DK3107562T3 (da) | 2014-02-19 | 2019-12-16 | Bioasis Technologies Inc | P97-ids-fusionsproteiner |
WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
TWI797430B (zh) | 2014-03-27 | 2023-04-01 | 中央研究院 | 反應性標記化合物及其用途 |
JP6750148B2 (ja) * | 2014-04-25 | 2020-09-02 | 公益財団法人野口研究所 | 糖鎖切断抗体の製造方法及び均一糖鎖抗体 |
CA2943890A1 (en) | 2014-05-01 | 2015-11-05 | Bioasis Technologies, Inc. | P97-polynucleotide conjugates |
TWI679020B (zh) | 2014-05-27 | 2019-12-11 | 中央研究院 | 抗her2醣抗體及其用途 |
CN107074945B (zh) | 2014-05-27 | 2021-08-24 | 中央研究院 | 增进抗体功效的通用糖型的组合物及方法 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
JP2017518989A (ja) | 2014-05-27 | 2017-07-13 | アカデミア シニカAcademia Sinica | 抗cd20糖操作抗体群およびその使用 |
EP3155017B1 (en) | 2014-05-28 | 2024-01-10 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
TWI732738B (zh) | 2014-05-28 | 2021-07-11 | 中央研究院 | 抗TNF-α醣抗體及其用途 |
WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
EP3682904A1 (en) | 2014-06-30 | 2020-07-22 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
AU2015287696B2 (en) * | 2014-07-10 | 2018-06-14 | Academia Sinica | Multi-drug delivery system and uses thereof |
PL3177317T3 (pl) | 2014-08-04 | 2020-07-27 | Csl Limited | Formulacja czynnika viii |
US9879042B2 (en) | 2014-09-08 | 2018-01-30 | Academia Sinica | Human iNKT cell activation using glycolipids |
CN113975406A (zh) * | 2014-10-09 | 2022-01-28 | 建新公司 | 糖工程化的抗体药物缀合物 |
US10889631B2 (en) | 2014-11-20 | 2021-01-12 | Cytonics Corporation | Therapeutic variant alpha-2-macroglobulin compositions |
EP3230438A2 (en) | 2014-12-12 | 2017-10-18 | University of Copenhagen | N-glycosylation |
MX2017008658A (es) | 2014-12-31 | 2018-02-23 | Checkmate Pharmaceuticals Inc | Inmunoterapia antitumoral combinada. |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
EP3789766A1 (en) | 2015-01-24 | 2021-03-10 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
EP3331608A4 (en) | 2015-08-03 | 2019-05-01 | Bioverativ Therapeutics Inc. | FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME |
SG11201805028RA (en) | 2016-01-08 | 2018-07-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
HUE060521T2 (hu) | 2016-01-08 | 2023-03-28 | Ascendis Pharma Growth Disorders As | A gyûrûn hordozó gyököt tartalmazó CNP elõvegyületek |
EP3400020A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
NZ743489A (en) | 2016-01-08 | 2022-09-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
CA3008017C (en) * | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
JP2019515876A (ja) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | N−グリカンおよびそのアレイのモジュール合成のための方法 |
MA45473A (fr) * | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | Inhibiteur de c1 estérase conjugué et ses utilisations |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
EP3464318B1 (en) | 2016-06-02 | 2021-04-21 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
AU2017336253B2 (en) | 2016-09-29 | 2023-02-23 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
JP6852397B2 (ja) * | 2016-12-28 | 2021-03-31 | 株式会社島津製作所 | 分析用試料の調製方法および分析方法 |
EP3568161A4 (en) | 2016-12-29 | 2020-09-02 | Development Center for Biotechnology | METHOD OF MANUFACTURING GLYCOPROTEIN DRUG CONJUGATES |
PT3583120T (pt) | 2017-02-17 | 2022-12-15 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
JP2020511499A (ja) | 2017-03-20 | 2020-04-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法 |
EP3652316A4 (en) | 2017-07-11 | 2021-04-07 | Synthorx, Inc. | INTEGRATION OF NON-NATURAL NUCLEOTIDES AND METHOD FOR THEREFORE |
MX2020001332A (es) | 2017-08-03 | 2020-09-09 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas. |
ES2930534T3 (es) | 2017-09-04 | 2022-12-16 | 89Bio Ltd | Conjugados de péptidos de FGF-21 mutantes y usos de los mismos |
AU2018374634A1 (en) | 2017-12-01 | 2020-05-28 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
EP3735295A1 (en) | 2018-01-03 | 2020-11-11 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
WO2019232283A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
AU2019404061A1 (en) * | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
KR20210123299A (ko) | 2019-02-06 | 2021-10-13 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
US20220041750A1 (en) * | 2020-08-07 | 2022-02-10 | Eutilex Co., Ltd. | Anti-her2/anti-4-1bb bispecific antibodies and uses thereof |
WO2022081895A1 (en) * | 2020-10-16 | 2022-04-21 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
US20230372528A1 (en) * | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
EP4267195A1 (en) * | 2020-12-24 | 2023-11-01 | Synaffix B.V. | Glycan-conjugated antibodies binding to fc-gamma receptor |
CN113429443B (zh) * | 2021-07-08 | 2023-07-25 | 江南大学 | 一种双唾液酸-甘露寡糖复合物及其合成方法 |
EP4225766A4 (en) * | 2021-12-20 | 2024-03-27 | 89Bio Inc | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID |
Family Cites Families (261)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
DE2433883C2 (de) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Verwendung von physiologisch aktiven Polypeptiden |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
CH596313A5 (da) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
US4385260A (en) | 1975-09-09 | 1983-05-24 | Beckman Instruments, Inc. | Bargraph display |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
IL63270A0 (en) | 1980-08-05 | 1981-10-30 | Univ Leland Stanford Junior | Eukaryotic autonomously replicating segment |
US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4975276A (en) | 1982-01-15 | 1990-12-04 | Cetus Corporation | Interferon-alpha 54 |
US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
US4748233A (en) | 1982-03-23 | 1988-05-31 | Bristol-Myers Company | Alpha-interferon Gx-1 |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
ES522556A0 (es) | 1982-05-19 | 1984-03-01 | Gist Brocades Nv | Procedimiento de obtencion de nuevas cepas de la levadura kluyveromyces. |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US5151511A (en) | 1982-09-16 | 1992-09-29 | Amgen Inc. | DNA encoding avian growth hormones |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DK168016B1 (da) | 1983-12-26 | 1994-01-17 | Kyowa Hakko Kogyo Kk | Derivat af humant interferon-gamma-polypeptid |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4761371A (en) | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
DE3684546D1 (de) | 1985-04-22 | 1992-04-30 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
EP0220200B1 (de) | 1985-04-30 | 1988-08-24 | Büro Patent AG | Anlage und verfahren zum automatischen zuführen von vollen kannen zu und zum abführen leerer kannen von spinnstellen einer spinnmaschine |
EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JPS6238172A (ja) | 1985-08-12 | 1987-02-19 | 株式会社 高研 | 抗血栓性医用材料の製造方法 |
US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPH0657152B2 (ja) | 1985-09-17 | 1994-08-03 | 中外製薬株式会社 | Csf遺伝子類 |
JPS63502795A (ja) | 1985-10-03 | 1988-10-20 | バイオジェン インコーポレイテッド | 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、dna配列、組換えdna分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法 |
IL80529A0 (en) | 1985-11-14 | 1987-02-27 | Daiichi Seiyaku Co | Method of producing peptides |
DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
IT1203758B (it) | 1986-03-27 | 1989-02-23 | Univ Roma | Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4894330A (en) | 1986-12-23 | 1990-01-16 | Cetus Corporation | Purification of recombinant beta-interferon incorporating RP-HPLC |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4857505A (en) * | 1987-03-09 | 1989-08-15 | American Cyanamid Company | Sustained release compositions for parenteral administration and their use |
CA1304020C (en) | 1987-03-23 | 1992-06-23 | Meher H. Irani | High level expression in yeast |
IL82834A (en) | 1987-06-09 | 1990-11-05 | Yissum Res Dev Co | Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom |
AR247761A1 (es) | 1987-07-28 | 1995-03-31 | Gist Brocades Nv | Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5252726A (en) | 1987-09-04 | 1993-10-12 | Novo Nordisk A/S | Promoters for use in aspergillus |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
GB8810808D0 (en) | 1988-05-06 | 1988-06-08 | Wellcome Found | Vectors |
JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
FR2631974B1 (fr) | 1988-05-31 | 1992-12-11 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
FR2638643B1 (fr) | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US6166183A (en) | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
AU630658B2 (en) | 1988-12-23 | 1992-11-05 | Genentech Inc. | Human dnase |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
US5475090A (en) | 1989-02-21 | 1995-12-12 | Boyce Thompson Institute For Plant Research | Gene coded for a polypeptide which enhances virus infection of host insects |
US5194376A (en) | 1989-02-28 | 1993-03-16 | University Of Ottawa | Baculovirus expression system capable of producing foreign gene proteins at high levels |
DE3906540A1 (de) | 1989-03-02 | 1990-09-13 | Behringwerke Ag | Expressionsvektoren zur synthese von proteinen in der spalthefe schizosaccharomyces pombe |
US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
ES2247656T3 (es) | 1989-04-19 | 2006-03-01 | Enzon, Inc. | Un proceso para formar un polipeptido modificado que comprende un polipeptido y un oxido de polialquileno. |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
ATE144281T1 (de) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der gattung-schwanniomyces |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
US5179007A (en) | 1989-07-07 | 1993-01-12 | The Texas A & M University System | Method and vector for the purification of foreign proteins |
US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5023328A (en) | 1989-08-04 | 1991-06-11 | The Texas A&M University System | Lepidopteran AKH signal sequence |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5182107A (en) | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5032519A (en) | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
DE4009630C2 (de) * | 1990-03-26 | 1995-09-28 | Reinhard Prof Dr Dr Brossmer | CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung |
JP2975632B2 (ja) * | 1990-03-30 | 1999-11-10 | 生化学工業株式会社 | グリコサミノグリカン修飾プロテイン |
US5606031A (en) | 1990-04-06 | 1997-02-25 | Lile; Jack | Production and purification of biologically active recombinant neurotrophic protein in bacteria |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
US5951972A (en) * | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
US5399345A (en) | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
US5492821A (en) * | 1990-11-14 | 1996-02-20 | Cargill, Inc. | Stabilized polyacrylic saccharide protein conjugates |
US5420027A (en) | 1991-01-10 | 1995-05-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the expression of biologically active fusion proteins comprising a eukaryotic cytochrome P450 fused to a reductase in bacteria |
US6288304B1 (en) | 1991-02-22 | 2001-09-11 | Sembiosys Genetics Inc. | Expression of somatotropin in plant seeds |
US5948682A (en) | 1991-02-22 | 1999-09-07 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
US5650554A (en) | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
EP0576592B1 (en) | 1991-03-18 | 2000-05-31 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
US5278299A (en) * | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
US5212075A (en) | 1991-04-15 | 1993-05-18 | The Regents Of The University Of California | Compositions and methods for introducing effectors to pathogens and cells |
US5472858A (en) | 1991-06-04 | 1995-12-05 | Wisconsin Alumni Research Foundation | Production of recombinant proteins in insect larvae |
US5374655A (en) | 1991-06-10 | 1994-12-20 | Alberta Research Council | Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures |
US5352670A (en) | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
KR950014915B1 (ko) * | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | 탈시알로당단백-포함화합물 |
US5352570A (en) | 1991-06-28 | 1994-10-04 | Eastman Kodak Company | Method and photographic material and process comprising a benzotriazole compound |
WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
US5633146A (en) | 1991-07-02 | 1997-05-27 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant proteins and host cells used therein |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
DK8892D0 (da) | 1992-01-23 | 1992-01-23 | Symbicom Ab | Humant proteingen |
IT1260468B (it) | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
US5965106A (en) | 1992-03-04 | 1999-10-12 | Perimmune Holdings, Inc. | In vivo binding pair pretargeting |
UA41319C2 (uk) | 1992-04-02 | 2001-09-17 | Сембайозіс Дженетікс Інк. | Спосіб експресії послідовності днк,що представляє інтерес,у клітині насіння,химерний ген,експресуюча касета,ізольована регуляторна ділянка транскрипції,спосіб зміни специфічного для насіння метаболізму, спосіб одержання нових поліпептидів у насінні,ізольована днк, спосіб експресії послідовності днк,що представляє інтерес,у рослині-хазяїні,спосіб одержання очищеного поліпептиду,що представляє інтерес,спосіб одержання поліпептиду, що представляє інтерес, в олійному тілі |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
CA2141673A1 (en) * | 1992-08-07 | 1994-02-17 | Graham P. Allaway | Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof |
WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5348886A (en) | 1992-09-04 | 1994-09-20 | Monsanto Company | Method of producing recombinant eukaryotic viruses in bacteria |
AU682837B2 (en) | 1992-11-27 | 1997-10-23 | Novartis Ag | Proteins having glycosyltransferase activity |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5202413A (en) | 1993-02-16 | 1993-04-13 | E. I. Du Pont De Nemours And Company | Alternating (ABA)N polylactide block copolymers |
US5374541A (en) | 1993-05-04 | 1994-12-20 | The Scripps Research Institute | Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides |
US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
JPH09503905A (ja) * | 1993-07-15 | 1997-04-22 | ネオゼ ファーマシューティカルス | 糖組成物の合成方法 |
DE4325317C2 (de) * | 1993-07-29 | 1998-05-20 | Univ Dresden Tech | Verfahren zur radioaktiven Markierung von Immunglobulinen |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
CA2179394A1 (en) | 1993-12-23 | 1995-06-29 | Kostas Iatrou | Methods of expressing proteins in insect cells and methods of killing insects |
US5597709A (en) | 1994-01-27 | 1997-01-28 | Human Genome Sciences, Inc. | Human growth hormone splice variants hGHV-2(88) and hGHV-3(53) |
US5369017A (en) * | 1994-02-04 | 1994-11-29 | The Scripps Research Institute | Process for solid phase glycopeptide synthesis |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
JP3090586B2 (ja) | 1994-03-15 | 2000-09-25 | 片倉工業株式会社 | システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法 |
US5545723A (en) | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5432059A (en) | 1994-04-01 | 1995-07-11 | Specialty Laboratories, Inc. | Assay for glycosylation deficiency disorders |
GB9408717D0 (en) | 1994-05-03 | 1994-06-22 | Biotech & Biolog Scien Res | DNA sequences |
ATE216425T1 (de) | 1994-08-13 | 2002-05-15 | Roche Diagnostics Gmbh | Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
WO1996010089A1 (fr) * | 1994-09-29 | 1996-04-04 | Ajinomoto Co., Inc. | Modification d'un peptide et d'une proteine |
US5521299A (en) | 1994-11-22 | 1996-05-28 | National Science Council | Oligonucleotides for detection of baculovirus infection |
US5834251A (en) | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
JPH11500014A (ja) | 1995-02-21 | 1999-01-06 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウイルス調製物、ベクター、免疫原、及びワクチン |
US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
GB9506249D0 (en) | 1995-03-27 | 1995-05-17 | Karobio Ab | Media for insect cell cultures |
US5922577A (en) | 1995-04-11 | 1999-07-13 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
US6030815A (en) | 1995-04-11 | 2000-02-29 | Neose Technologies, Inc. | Enzymatic synthesis of oligosaccharides |
US5728554A (en) | 1995-04-11 | 1998-03-17 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
US5876980A (en) | 1995-04-11 | 1999-03-02 | Cytel Corporation | Enzymatic synthesis of oligosaccharides |
WO1996036357A1 (en) * | 1995-05-15 | 1996-11-21 | Bona Constantin A | Carbohydrate-mediated coupling of peptides to immunoglobulins |
US6015555A (en) | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5811634A (en) | 1995-09-12 | 1998-09-22 | Thomas G. O'Brien | Transgenic mammal encoding ornithine decarboxylase |
DE69638117D1 (de) * | 1995-09-21 | 2010-03-04 | Genentech Inc | Varianten des menschlichen Wachstumshormons |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US5767379A (en) | 1995-11-06 | 1998-06-16 | John Howard | Commercial production of avidin in plants |
CA2237120C (en) | 1995-11-09 | 2005-03-01 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in pichia methanolica |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US5716812A (en) | 1995-12-12 | 1998-02-10 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides, and the products formed thereby |
US5728580A (en) | 1996-02-20 | 1998-03-17 | Cornell Research Foundation, Inc. | Methods and culture media for inducing single cell suspension in insect cell lines |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US5734024A (en) | 1996-04-19 | 1998-03-31 | Boris Y. Zaslavsky | Method for determining the biological activity of recombinant human growth hormone |
US5750383A (en) | 1996-05-14 | 1998-05-12 | Boyce Thompson Institute For Plant Research, Inc. | Baculovirus cloning system |
JP2002514049A (ja) | 1996-07-17 | 2002-05-14 | ザイモジェネティクス,インコーポレイティド | ピヒア・メタノリカの栄養要求性突然変異体の製造 |
WO1998002565A1 (en) | 1996-07-17 | 1998-01-22 | Zymogenetics, Inc. | TRANSFORMATION OF $i(PICHIA METHANOLICA) |
US5682823A (en) | 1996-08-23 | 1997-11-04 | Bethlehem Steel Corporation | Removable insulated cover and method for transporting hot oversized steel ingots |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
HUP0001634A2 (hu) | 1996-10-10 | 2000-09-28 | Cytel Corporation | Szénhidrátok tisztítása ultraszűréssel, fordított ozmózissal és nanoszűréssel |
US5856452A (en) | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
BR9606270A (pt) | 1996-12-18 | 1998-09-22 | Univ Minas Gerais | Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante |
WO1998031826A1 (en) | 1997-01-16 | 1998-07-23 | Cytel Corporation | Practical in vitro sialylation of recombinant glycoproteins |
US5945314A (en) * | 1997-03-31 | 1999-08-31 | Abbott Laboratories | Process for synthesizing oligosaccharides |
US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US7585645B2 (en) | 1997-05-27 | 2009-09-08 | Sembiosys Genetics Inc. | Thioredoxin and thioredoxin reductase containing oil body based products |
DE69837170T2 (de) | 1997-06-13 | 2007-11-22 | Amylin Pharmaceuticals, Inc., San Diego | Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen |
US6210736B1 (en) | 1997-06-17 | 2001-04-03 | Genzyme Transgenics Corporation | Transgenically produced prolactin |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
WO1999000150A2 (en) | 1997-06-27 | 1999-01-07 | Regents Of The University Of California | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
US6090584A (en) | 1997-08-21 | 2000-07-18 | University Technologies International Inc. | Baculovirus artificial chromosomes and methods of use |
GB9722604D0 (en) * | 1997-10-28 | 1997-12-24 | Cancer Res Campaign Tech | Heparin-binding growth factor derivatives |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
AU1808699A (en) | 1997-12-08 | 1999-06-28 | Board Of Trustees Of The University Of Arkansas, The | Purified beta1,2-xylosyltransferase and uses thereof |
US7244601B2 (en) | 1997-12-15 | 2007-07-17 | National Research Council Of Canada | Fusion proteins for use in enzymatic synthesis of oligosaccharides |
US6362276B1 (en) | 1998-01-07 | 2002-03-26 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
AR014491A1 (es) | 1998-01-29 | 2001-02-28 | Dow Agrosciences Llc | Metodo para obtener plantas transgenicas fertiles de gossypium hirsutum. |
ATE268609T1 (de) | 1998-03-12 | 2004-06-15 | Nektar Therapeutics Al Corp | Polyethylenglycolderivate mit benachbarten reaktiven gruppen |
US6689604B1 (en) | 1998-03-20 | 2004-02-10 | National Research Council Of Canada | Lipopolysaccharide α-2,3 sialyltransferase of Campylobacter jejuni and its uses |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
CA2345356C (en) | 1998-10-06 | 2012-10-02 | Mark Aaron Emalfarb | Transformation system in the field of filamentous fungal hosts |
US6245539B1 (en) | 1998-10-06 | 2001-06-12 | Board Of Trustees Operating Michigan State University | Human asparaginyl-tRNA synthetase DNA |
EP2599503B1 (en) * | 1998-10-16 | 2017-05-17 | Biogen MA Inc. | Polymer conjugates of interferon beta-1A and uses thereof |
US6374295B2 (en) * | 1998-10-29 | 2002-04-16 | Nortel Networks Limited | Active server management |
DE19852729A1 (de) * | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
WO2000029603A2 (en) * | 1998-11-18 | 2000-05-25 | Neose Technologies, Inc. | Low cost manufacture of oligosaccharides |
CN1214043C (zh) | 1998-12-01 | 2005-08-10 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
IL144361A0 (en) * | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
US6365410B1 (en) | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
WO2001005434A2 (en) * | 1999-07-20 | 2001-01-25 | Amgen Inc. | Hyaluronic acid-protein conjugates |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US6376604B2 (en) | 1999-12-22 | 2002-04-23 | Shearwater Corporation | Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol) |
IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
BR0107561A (pt) * | 2000-01-10 | 2002-11-19 | Maxygen Holdings Ltd | Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos |
US6423488B1 (en) | 2000-01-15 | 2002-07-23 | Avigenics, Inc | High throughput screening assay for detecting a DNA sequence |
AU2001232337A1 (en) | 2000-02-18 | 2001-08-27 | Kanagawa Academy Of Science And Technology | Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance |
NZ523476A (en) | 2000-06-28 | 2004-04-30 | Glycofi Inc | Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes |
CA2412882A1 (en) | 2000-06-30 | 2002-01-10 | Maxygen Aps | Peptide extended glycosylated polypeptides |
WO2002004512A2 (en) | 2000-07-10 | 2002-01-17 | Diosynth Rtp, Inc. | Purification of human troponin i |
AU2001283740A1 (en) | 2000-08-17 | 2002-02-25 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
WO2002013873A2 (en) | 2000-08-17 | 2002-02-21 | Synapse Technologies, Inc. | P97-active agent conjugates and their methods of use |
IL156059A0 (en) | 2001-02-27 | 2003-12-23 | Maxygen Aps | NEW INTERFERON beta-LIKE MOLECULES |
JP5232352B2 (ja) | 2001-10-10 | 2013-07-10 | ノボ ノルデイスク エイ エス | ペプチドの改造および複合糖質化 |
JP3894776B2 (ja) | 2001-11-09 | 2007-03-22 | 富士通メディアデバイス株式会社 | 吐出装置および吐出方法 |
RU2362807C2 (ru) * | 2002-06-21 | 2009-07-27 | Ново Нордиск Хелт Кэр Аг | Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция |
WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
JP4251399B2 (ja) * | 2004-05-21 | 2009-04-08 | 独立行政法人産業技術総合研究所 | O結合型糖鎖が付加されたペプチドのスクリーニング方法 |
-
2002
- 2002-10-09 JP JP2003534446A patent/JP5232352B2/ja not_active Expired - Lifetime
- 2002-10-09 ES ES10012794.3T patent/ES2538342T3/es not_active Expired - Lifetime
- 2002-10-09 ES ES10012536.8T patent/ES2556338T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP10012536.8A patent/EP2279753B1/en not_active Expired - Lifetime
- 2002-10-09 SG SG2006055305A patent/SG177002A1/en unknown
- 2002-10-09 ES ES09151346.5T patent/ES2564688T3/es not_active Expired - Lifetime
- 2002-10-09 WO PCT/US2002/032263 patent/WO2003031464A2/en active Application Filing
- 2002-10-09 US US10/492,261 patent/US7416858B2/en not_active Expired - Lifetime
- 2002-10-09 EP EP10012938.6A patent/EP2279754B1/en not_active Expired - Lifetime
- 2002-10-09 DK DK02795509.5T patent/DK1578771T3/da active
- 2002-10-09 BR BRPI0213207-9A patent/BRPI0213207B1/pt not_active IP Right Cessation
- 2002-10-09 CN CN02820073XA patent/CN1635901B/zh not_active Expired - Lifetime
- 2002-10-09 ES ES02795509T patent/ES2411007T3/es not_active Expired - Lifetime
- 2002-10-09 PT PT100125368T patent/PT2279753E/pt unknown
- 2002-10-09 MX MXPA04003333A patent/MXPA04003333A/es active IP Right Grant
- 2002-10-09 EP EP10012795A patent/EP2292271A3/en not_active Withdrawn
- 2002-10-09 ES ES10184886T patent/ES2619371T3/es not_active Expired - Lifetime
- 2002-10-09 CN CN2011100354568A patent/CN102180944A/zh active Pending
- 2002-10-09 SG SG200605529-7A patent/SG159381A1/en unknown
- 2002-10-09 DK DK10184886.9T patent/DK2322229T3/da active
- 2002-10-09 ES ES09000818.6T patent/ES2606840T3/es not_active Expired - Lifetime
- 2002-10-09 ES ES10012938.6T patent/ES2516041T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP09000818.6A patent/EP2042196B1/en not_active Expired - Lifetime
- 2002-10-09 EP EP09151346.5A patent/EP2080525B1/en not_active Expired - Lifetime
- 2002-10-09 EP EP02795509A patent/EP1578771B1/en not_active Expired - Lifetime
- 2002-10-09 CA CA2462930A patent/CA2462930C/en not_active Expired - Lifetime
- 2002-10-09 IL IL16125102A patent/IL161251A0/xx unknown
- 2002-10-09 NZ NZ532027A patent/NZ532027A/en not_active IP Right Cessation
- 2002-10-09 PT PT100129394T patent/PT2279755E/pt unknown
- 2002-10-09 ES ES10012798T patent/ES2561985T3/es not_active Expired - Lifetime
- 2002-10-09 EP EP10012939.4A patent/EP2279755B1/en not_active Expired - Lifetime
- 2002-10-09 CN CN200910145812.4A patent/CN101724075B/zh not_active Expired - Lifetime
- 2002-10-09 AU AU2002360264A patent/AU2002360264B2/en not_active Expired
- 2002-10-09 ES ES10012939.4T patent/ES2466024T3/es not_active Expired - Lifetime
- 2002-11-05 US US10/287,994 patent/US7138371B2/en active Active
-
2004
- 2004-04-01 IL IL161251A patent/IL161251A/en active IP Right Grant
-
2005
- 2005-12-23 HK HK05111922.5A patent/HK1079797A1/xx not_active IP Right Cessation
- 2005-12-23 HK HK11107561.1A patent/HK1149513A1/xx not_active IP Right Cessation
-
2006
- 2006-01-04 HK HK06100136.9A patent/HK1080090B/zh not_active IP Right Cessation
- 2006-04-12 US US11/404,266 patent/US7276475B2/en not_active Expired - Lifetime
-
2008
- 2008-11-20 JP JP2008297209A patent/JP5376912B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-16 AU AU2009202405A patent/AU2009202405B2/en not_active Expired
-
2010
- 2010-02-05 JP JP2010024516A patent/JP5258809B2/ja not_active Expired - Lifetime
- 2010-09-28 JP JP2010217733A patent/JP5739632B2/ja not_active Expired - Fee Related
- 2010-12-23 IL IL210257A patent/IL210257A/en not_active IP Right Cessation
-
2011
- 2011-08-18 HK HK11108713.6A patent/HK1154498A1/xx not_active IP Right Cessation
-
2012
- 2012-05-07 JP JP2012106130A patent/JP2012143250A/ja active Pending
-
2014
- 2014-01-23 LU LU92359C patent/LU92359I2/fr unknown
- 2014-01-24 BE BE2014C004C patent/BE2014C004I2/fr unknown
- 2014-01-24 FR FR14C0007C patent/FR14C0007I2/fr active Active
- 2014-01-28 JP JP2014013799A patent/JP2014087370A/ja not_active Ceased
-
2015
- 2015-09-17 JP JP2015184218A patent/JP6316784B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-14 JP JP2016118316A patent/JP6321724B2/ja not_active Expired - Lifetime
-
2017
- 2017-11-21 NL NL300912C patent/NL300912I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1578771T3 (da) | Remodellering og glycokonjugering af peptider | |
DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
FR17C1053I2 (fr) | Remodelage et glycoconjugation de facteur ix | |
DK1746375T3 (da) | Oxygendrevet forbrændingssystem og anvendelser deraf | |
DE50204020D1 (de) | Mikrotom | |
DK1554250T3 (da) | Hidtil ukendt lactamer og anvendelser deraf | |
DK1410012T3 (da) | Bestemmelse af graviditetstilstand | |
NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
NO20035370D0 (no) | Karakterisere polypeptider | |
DE60239866D1 (de) | Fischer-tropsch-verfahren | |
NO20035369D0 (no) | Karakterisere polypeptider | |
IS6884A (is) | Aðferðir við að nýta líffræðilegan fjölbreytileika | |
DK1390516T3 (da) | Hidtil ukendte ekspressionsvektorer og anvendelser deraf | |
ATE523892T1 (de) | Klemmhilfe | |
NO20032963L (no) | Peptidforbindelser | |
DK1256754T3 (da) | Spændebånd | |
DE60210915D1 (de) | Text-zu-Sprache Umsetzung | |
DE60232564D1 (de) | Fixiergerät | |
NO20020080D0 (no) | Sekvenser og fremgangsmåter for deteksjon av HIV-1 | |
NO20013244D0 (no) | Forgreningspunkt | |
DE60112036D1 (de) | Uhrwerk | |
FR2833506B3 (fr) | Serre-joint | |
NO20013036L (no) | HC-dekkgass | |
CA93592S (fr) | Guitare | |
FIU20000376U0 (fi) | Laituri |